Abstract
Background
Although recent reports indicate that K-ras mutation status is a biomarker that acts as a prognostic factor, only a few analyses of K-ras mutation subtypes have been published. In addition, there are no reports that analyze overall survival and prognostic factors according to K-ras mutation status and subtypes in only unresectable pancreatic cancer (PC) determined from tissues obtained by endoscopic ultrasound-guided fine-needle aspiration.
Methods
We retrospectively analyzed 242 patients who were diagnosed as having unresectable PC with available histological diagnosis. Clinical data collected included sex, age, Eastern Cooperative Oncology Group performance status, carbohydrate antigen (CA) 19-9, primary tumor location, stage (local or metastatic) according to TNM staging, first-line chemotherapy, K-ras mutation status and subtypes (G12D, G12V, and G12R), and overall survival. We analyzed the negative prognostic factors for reduced overall survival in unresectable PC patients using these data.
Results
From multivariate analysis, CA19-9 ≥1000 U/ml (hazard ratio [HR] 1.78, 95 % confidence interval [CI] 1.28–2.46, P < 0.01), metastatic stage (HR 2.26, 95 % CI 1.58–3.24, P < 0.01), and mutant-K-ras (HR 1.76, 95 % CI 1.03–3.01, P = 0.04) were negative prognostic factors, indicating a reduced survival. Among the patients who had K-ras mutation subtypes, CA19-9 ≥1000 U/ml (HR 1.65, 95 % CI 1.12–2.37, P < 0.01), metastatic stage (HR 2.12, 95 % CI 1.44–3.14, P < 0.01), and the presence of the G12D or G12R mutations (HR 1.60, 95 % CI 1.11–2.28) were negative prognostic factors for overall survival.
Conclusions
K-ras mutation status and subtypes may be associated with survival duration in pancreatic cancer patients.
Similar content being viewed by others
References
Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer. 1987;60:2284–303.
Warshaw AL. Fernandez del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65.
Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006;107:2589–96.
Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148–54.
Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, et al. Practical prognosis index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008;23:1292–7.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–54.
Tada M, Omata M, Ohto M. Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. Gastroenterology. 1991;100:233–8.
Kullmann F, Hartmann A, Stohr R, Messmann H, Dollinger MM, Trojan J, et al. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy. Oncology. 2011;81:3–8.
Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007;109:1561–9.
Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36:657–62.
Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000;89:469–74.
Immervoll H, Hoem D, Kuqarajh K, Steine SJ, Molven A. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788–96.
Ogura T, Yamao K, Sawaki A, Mizuno M, Hara K, et al. Clinical impact of K-ras mutation analysis in Endoscopic ultrasound-guided fine needle aspiration specimens from pancreatic masses. Gastrointest Endosc. 2012;75:769–74.
Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc. 1997;45:387–93.
Yamao K, Sawaki A, Mizuno N, Shimizu Y, Yatabe Y, Koshikawa T. Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB): past, present, and future. J Gastroenterol. 2005;40:1013–23.
Yatabe Y, Koqa T, Mitsudomi T, Takahashi T. CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol. 2004;203:645–52.
Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006;8:335–41.
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:1413–7.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.
Cox DR. Regression models and life-tables. J R Stat Soc B. 1984;34:588–91.
Rozenblum E, Shutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731–4.
Hiyama E, Kodama T, Shinbara K, Iwao T, Itho M, Hiyama K, et al. Telomerase activity is deleted in pancreatic cancer but not in benign tumors. Cancer Res. 1997;57:326–31.
Koorstra JBM, Hustinx SR, Offerhaus GJA, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110–25.
Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
Hruban RH, Goggins M, Parsons J, Kem SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969–72.
Span M, Moerkerek PT, De Goeij AF, Arends JW. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer. 1996;69:241–5.
Andreyev NJH, Norman AR, Cunningham D, Oates J, Dix BR, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study. Br J Cancer. 2001;85:692–6.
Vega J, Iniesta P, Caldes T, Sanchez A, Lopez J, Dejuan C, et al. Association of K-ras codon 12 transversions with short survival in non-small cell lung cancer. Int J Oncol. 1996;9:1307–11.
Keohavong P, Demichele MAA, Melacrions AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas-relationship to prognosis. Clin Cancer Res. 1999;2:411–8.
John J, Frech M, Wittinghofer A. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation resection. J Biol Chem. 1998;263:792–9.
Krengle U, Schlichting L, Scherer A, Schumann R, Frech M, John J, et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. J Biol Chem. 1989;264:86–92.
Al-Mulla F, Mackenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol. 2001;195:549–56.
Conflict of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogura, T., Yamao, K., Hara, K. et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 48, 640–646 (2013). https://doi.org/10.1007/s00535-012-0664-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-012-0664-2